These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Competitive enzyme mechanisms in the therapy of hemoblastosis using antimetabolites]. Wilmanns W Verh Dtsch Ges Inn Med; 1968; 74():822-30. PubMed ID: 4977259 [No Abstract] [Full Text] [Related]
4. Comparison of the effects of several inhibitors of the synthesis of nucleic acids upon the viability and progression through the cell cycle of cultured H. Ep. no. 2 cells. Wheeler GP; Bowdon BJ; Adamson DJ; Vail MH Cancer Res; 1972 Dec; 32(12):2661-9. PubMed ID: 4264728 [No Abstract] [Full Text] [Related]
5. [Various aspects of the problem of selectivity in the chemotherapy of cancer]. Velousova AK Vopr Onkol; 1969; 15(8):96-110. PubMed ID: 4901626 [No Abstract] [Full Text] [Related]
6. Cancer chemotherapy: mechanisms of action. Conroy JF Semin Drug Treat; 1973; 3(1):5-14. PubMed ID: 4541416 [No Abstract] [Full Text] [Related]
7. [Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II]. Grignani F; Martelli M; Tonato M Clin Ter; 1974 Apr; 69(2):153-76. PubMed ID: 4134598 [No Abstract] [Full Text] [Related]
8. Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture. Hitchings GH Cancer Res; 1969 Nov; 29(11):1895-903. PubMed ID: 4982548 [No Abstract] [Full Text] [Related]
9. [Possible applications of antivitamins and antimetabolites in therapy]. Frick PG Bibl Nutr Dieta; 1966; 8():6-16. PubMed ID: 5950495 [No Abstract] [Full Text] [Related]
10. [Regulation of purine metabolism and its modification by drugs]. Müller MM; Kaiser E Dtsch Med Wochenschr; 1975 Jan; 100(5):198-204. PubMed ID: 1112235 [No Abstract] [Full Text] [Related]
12. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682 [TBL] [Abstract][Full Text] [Related]
13. Antimetabolites. Grem JL; Chabner BA; Chu E; Johnson P; Yeh GC; Allegra CJ Cancer Chemother Biol Response Modif; 1991; 12():1-25. PubMed ID: 1834143 [No Abstract] [Full Text] [Related]
14. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations. Kim K; Blechman WJ; Riddle VG; Pardee AB Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006 [TBL] [Abstract][Full Text] [Related]
15. BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS). BROCKMAN RW; ANDERSON EP Annu Rev Biochem; 1963; 32():463-512. PubMed ID: 14144487 [No Abstract] [Full Text] [Related]
17. Pancytopenia due to the interaction of allopurinol with azathioprine or mercaptopurine. Prescrire Int; 2000 Apr; 9(46):50. PubMed ID: 11503788 [TBL] [Abstract][Full Text] [Related]
18. A GROWING SPECTRUM FOR THE ANTIMETABOLITES. HART GD Appl Ther; 1964 Jul; 6():596-8. PubMed ID: 14179437 [No Abstract] [Full Text] [Related]
19. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Tidd DM; Paterson AR Cancer Res; 1974 Apr; 34(4):738-46. PubMed ID: 4856046 [No Abstract] [Full Text] [Related]
20. Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. Wilkoff LJ; Wilcox WS; Burdeshaw JA; Dixon GJ; Dulmadge EA J Natl Cancer Inst; 1967 Nov; 39(5):965-75. PubMed ID: 6071005 [No Abstract] [Full Text] [Related] [Next] [New Search]